Literature DB >> 21577013

Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.

Dirk O Bauerschlag1, Ole Ammerpohl, Karen Bräutigam, Christian Schem, Qiong Lin, Marion T Weigel, Felix Hilpert, Norbert Arnold, Nicolai Maass, Ivo Meinhold-Heerlein, Wolfgang Wagner.   

Abstract

OBJECTIVE: Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis. Epigenetic modifications have been shown to play an important role in tumor development and formation. Therefore, global analysis of DNA methylation patterns might reveal specific CpG sites that correlate with progression-free interval (PFI) after therapy.
METHODS: Twenty samples of advanced ovarian cancer with a predominantly serous papillary histological subtype were subjected to DNA methylation profiling. Illumina HumanMethylation27 BeadChip technology was used for simultaneous analysis of 27,578 CpG sites in >14,000 genes.
RESULTS: Differential DNA methylation of various cytosines correlated with PFI. However, this becomes only significant by classification according to PFI with a cutoff of >28 months. Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). Gene ontology analysis revealed that differentially methylated genes were significantly overrepresented in the categories telomere organization, mesoderm development and immune regulation.
CONCLUSION: Epigenetic modifications at specific CpG sites correlate with PFI in ovarian cancer. Therefore, such analysis might be of prognostic value.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21577013     DOI: 10.1159/000327746

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  27 in total

1.  Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.

Authors:  Adnen Faddaoui; Razan Sheta; Magdalena Bachvarova; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stephane Gobeil; Chantale Morin; Karim Ghani; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2017-02-22       Impact factor: 4.534

Review 2.  Epigenetics in ovarian cancer.

Authors:  Yanina Natanzon; Ellen L Goode; Julie M Cunningham
Journal:  Semin Cancer Biol       Date:  2017-08-03       Impact factor: 15.707

3.  Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer.

Authors:  Dongyan Wu; Haitao Yang; Stacey J Winham; Yanina Natanzon; Devin C Koestler; Tiane Luo; Brooke L Fridley; Ellen L Goode; Yanbo Zhang; Yuehua Cui
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

4.  Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus.

Authors:  Rihong Zhai; Yang Zhao; Li Su; Lauren Cassidy; Geoffrey Liu; David C Christiani
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

5.  Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Authors:  Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-23       Impact factor: 4.553

6.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

7.  Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.

Authors:  Rui-Lan Huang; Fei Gu; Nameer B Kirma; Jianhua Ruan; Chun-Liang Chen; Hui-Chen Wang; Yu-Ping Liao; Cheng-Chang Chang; Mu-Hsien Yu; Jay M Pilrose; Ian M Thompson; Hsuan-Cheng Huang; Tim Hui-Ming Huang; Hung-Cheng Lai; Kenneth P Nephew
Journal:  Epigenetics       Date:  2013-05-10       Impact factor: 4.528

8.  The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer-promoter interactions.

Authors:  Zhangwei Tong; Yonghong Liu; Xiaobin Yu; Jarrod D Martinez; Jianming Xu
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

Review 9.  DNA methylation changes in epithelial ovarian cancer histotypes.

Authors:  Madalene A Earp; Julie M Cunningham
Journal:  Genomics       Date:  2015-09-10       Impact factor: 5.736

10.  GREB1 isoforms regulate proliferation independent of ERα co-regulator activities in breast cancer.

Authors:  Corinne N Haines; Kara M Braunreiter; Xiaokui Molly Mo; Craig J Burd
Journal:  Endocr Relat Cancer       Date:  2018-04-25       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.